

Grass Pollen Allergy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G32C624E6D3EN.html>

Date: February 2020

Pages: 78

Price: US\$ 2,000.00 (Single User License)

ID: G32C624E6D3EN

Abstracts

Grass Pollen Allergy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II and Preclinical stages are 2, 4 and 2 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Grass Pollen Allergy - Overview
- Grass Pollen Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Grass Pollen Allergy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Grass Pollen Allergy - Companies Involved in Therapeutics Development
- ALK-Abello AS
- Allergy Therapeutics Plc
- ASIT Biotech SA
- Biomay AG
- DC4U BV
- HAL Allergy BV
- Regeneron Pharmaceuticals Inc
- Grass Pollen Allergy - Drug Profiles
- Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BM-32 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dupilumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- gp-ASIT - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Grass Pollen Allergy - Dormant Projects

Grass Pollen Allergy - Discontinued Products

Grass Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Dec 20, 2019: ASIT biotech discloses next steps following gp-ASIT+ phase III results

Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme

Nov 25, 2019: ASIT biotech gp-ASIT+ phase III trial in Grass Pollen Allergy did not meet the primary endpoint

Oct 17, 2019: ASIT biotech mode of action study of gp-ASIT+ for Grass Pollen Allergy published in The Journal of Allergy and Clinical Immunology (JACI)

Sep 26, 2019: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy

Sep 05, 2019: Successful pollen season confirms Asit Biotech on track for phase III results of gp-ASIT+ in December 2019

Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial

May 02, 2019: ASIT biotech announces the achievement of new clinical and corporate development milestones

Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update

Mar 29, 2019: ASIT biotech's scientific advisory boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+

Mar 05, 2019: ASIT biotech Reveals the Mode of Action of Its Lead Immunotherapy Product for Allergic Rhinitis, gp-ASIT+, in The Journal of Allergy and Clinical Immunology (JACI)

Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis

Jan 16, 2019: Ongoing Restructuring of ASIT biotech Organization to Maximize the Success of gp-ASIT+ in Grass Pollen Rhinitis

Nov 19, 2018: ASIT biotech launches its confirmatory phase III clinical study with gp-ASIT+ in grass pollen rhinitis prevention following the investigator meeting hosted in Prague (Czech Republic)

Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Grass Pollen Allergy, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Grass Pollen Allergy - Pipeline by ALK-Abello AS, H1 2020

Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2020

Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H1 2020

Grass Pollen Allergy - Pipeline by Biomay AG, H1 2020

Grass Pollen Allergy - Pipeline by DC4U BV, H1 2020

Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2020

Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Grass Pollen Allergy - Dormant Projects, H1 2020

Grass Pollen Allergy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Grass Pollen Allergy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

DC4U BV

HAL Allergy BV

Regeneron Pharmaceuticals Inc

I would like to order

Product name: Grass Pollen Allergy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G32C624E6D3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G32C624E6D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970